Dignitana AB Publishes Q4 2023 Interim Report
Positive EBITDA, continued growth and high margin
Financial highlights Q4 2023
- Net sales amounted to 22.2 MSEK (18.6), an increase of 19 percent over the same period in 2022.
- Operating result amounted to-3.1 MSEK (-3.6).
- Net result after financial items amounted to-3.7 MSEK (-3.7).
- EBITDA for the Third Quarter is positive at 674 TSEK (-119).
- Earnings per share were-0.05 SEK (-0.06).
- Cash Balance amounted to 7.0 MSEK (6.7).
- Average Daily Treatment Revenue (ADTR)* was 237 TSEK (203), an increase of 17 percent over the same period in 2022
Financial highlights Full Year 2023
- Net sales amounted to 86.1 MSEK (73.0), an increase of 18 percent over 2022.
- Operating Result amounted to-15.0 MSEK (-20.6).
- Net Result after financial items amounted to-17.4 MSEK (-22.4).
- EBITDA for the year is positive at 0.1 MSEK (-6.8).
- Earnings per share were-0.25 SEK (-0.34)
Business highlights during the period
- Dignitana announced a sales and marketing partnership with InfuSystem to provide scalp in the United States.
- Seven states in the southeastern United States fall under the Local Coverage Determination issued by Palmetto GBA providing coverage for scalp cooling to Medicare recipients as of November 2023.
- Dignitana announced the US Centers for Medicare & Medicaid Services will continue to support scalp cooling however at a reduced average rate beginning January 2024.
- Dignitana AB appointed the Nomination Committee for the 2024 Annual General Meeting
Business highlights after the period
- Dignitana convenes Training Academy bringing distributors to Lund Headquarters
- Preliminary results of DigniCap Delta study in Uruguay demonstrate very high efficacy compared to previous studies.
- Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein
- DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana’s Distribution partner
Business highlights Full Year 2023
- Science International Corporation was announced as Dignitana's distributor in Hong Kong and Macao.
- Dignitana co-sponsored a scalp cooling session at the Multinational Association of Supportive Care in Cancer conference in Japan along with exhibiting at the conference.
- A Medicare Local Coverage Determination for Medicare for scalp cooling therapy took effect in seven states in the southeastern US.
- Five year follow up results from the DigniCap pivotal trial were published in the Supportive Care in Cancer journal demonstrating both safety and efficacy in the first long term study of scalp cooling
- Dignitanas's partnership with oneservice expanded to provide service in the field to DigniCap customers in Europe.
- DigniCap Delta was introduced to customers in Mexico by Celeritas, DigniCap’s longtime partner.
Key Figures
| DIGNITANA GROUP | Q4 2023 | Q4 2022 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net sales, TSEK | 21,266 | 20,245 | 86,063 | 72 995 |
| Total revenues, TSEK | 21,916 | 21,421 | 89,025 | 83 849 |
| Net profit after financial items, TSEK | -4,943 | -11,996 | -17,228 | -22 396 |
| Cash and bank balances, TSEK | 6,027 | 8,869 | 6,027 | 8 869 |
| Earnings per share before and after dilution, SEK | -0.07 | -0.17 | -0.25 | -0.34 |
| verage Daily Treatment revenue, TSEK | 238 | 229 | 239 | 203 |
* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
"With a strong focus on establishing stable operating expenses to support our scale up strategy, we have grown with high margin while reducing loss." – Catarina Löwenadler, CEO
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-02-2024 08:05 CET.
